The Epidemiology and Trend of Cancer in Misurata oncology center, 2012–2016
Abstract
BACKGROUND: on the last decade in Libya, the oncology center in Misurata become the most important cancer diagnosis and follow up center on the western region of Libya. The Libyan society was worried about the increase of the percentage of tumor incidences among the Libyans on the last few years. This study focuses on cancer prevalence in city of Misurata and the surrounding area in central Libya from 2012 to 2016.
METHODS: A hospital-based registry of cancer patients was formed using records from oncology center in Misurata, focusing on patients who were diagnosed between 2012 and 2016.
RESULTS: the incidence of tumor on females was higher than males from 2014 up to higher deference on 2016, the most common malignancies in men were cancers of the lung on years from 2012 up to 2015 even though it decrease to 18% of males patients on 2016, followed by colon, its prevalence rate ranged from 14% to 18% of recorded male patients (For women, they were found to be cancers of the breast ranged from 29.84% on 2012 and raised to 43.08%. Additionally, age-standardized rates (ASR) were determined for recording patients who leaved on the city of Misurata and compared with published record from the other countries. The incidence rates given for the city of Misurata can be considered with the counties with low malignancy rate
CONCLUSION: Proper surveillance programs need to be in place and healthcare policy should be adjusted to consider the more prevalent and pressing cancers in society.
References
2. Forman D, Ferlay J, Stewart BW, Wild CP. The global and regional burden of cancer. In: Stewart BW, Wild CP. World Cancer Report 2014. Lyon France: International Agency for Research on Cancer, 2014:16-53.
3. Segi M. Cancer mortality for selected sites in 24 countries, Sendai, Japan: Department of Public Health, Tohoku University of Medicine, 1960;p. 1950–7.
4. Doll R, Payne P, Waterhouse JAH, eds. Cancer incidence in five continents, Vol, Geneva: I. Union Internationale Contre le Cancer, 1966.
5. Bureau of Statistics and Census Libya. Available from: http://www.bsc.ly/?P=5&sec_Id=18&dep_Id=6/. [Last accessed on 2017 Mar 28].
6. Silva IS. Cancer Epidemiology: Principals and Methods. WH-International Agency for Research on Cancer, Lyon-France; 1999. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/cancerepi/CancerEpi.pdf. [Last accessed on 2018 Feb 15].
7. Giordano, L., Bisanti, L., Salamina, G., Ancelle Park, R., Sancho-Garnier, H., Espinas, J., Berling, C., Rennert, G., Castagno, R., Dotti, M., Jaramillo, L., & Segnan, N. (2016). The EUROMED CANCER network: State-of-art of cancer screening programmes in non-EU Mediterranean countries. European Journal of Public Health, 26(1). https://doi.org/10.1093/eurpub/ckv107
8. Khader, Y. S., Sharkas, G. F., Arkoub, K. H., Alfaqih, M. A., Nimri, O. F., & Khader, A. M. (2018). The epidemiology and trend of cancer in Jordan, 2000–2013. Journal of Cancer Epidemiology, 2018. https://doi.org/10.1155/2018/2937067
9. Bazarbashi, S., al Eid, H., & Minguet, J. (2017). Cancer incidence in Saudi Arabia: 2012 data from the Saudi cancer registry. Asian Pacific Journal of Cancer Prevention, 18(9). https://doi.org/10.22034/APJCP.2017.18.9.2437
10. Radwan, H., Hasan, H., Ballout, R. A., & Rizk, R. (2018). The epidemiology of cancer in the United Arab Emirates :A systematic review. In Medicine (United States) (Vol. 97, Issue 50). https://doi.org/10.1097/MD.0000000000013618.
11. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6). https://doi.org/10.3322/caac.21492
12. Anton-Culver, H., et al. (2016). "Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir (Turkey)) with comparison to the United States surveillance; epidemiology and end results program." Cancer Epidemiol 44: 195-202.
